Akari Therapeutics

About:

Akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics.

Website: https://www.akaritx.com

Top Investors: Deerfield, RA Capital Management, New Enterprise Associates, Foresite Capital, Vivo Capital

Description:

Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, Nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity. Nomacopan is currently being clinically evaluated in four areas: bullous pemphigoid (BP), thrombotic microangiopathy (TMA), as well as programs in the eye and lung.